| Literature DB >> 32672839 |
Zhihua Ran1, Kaichun Wu2, Katsuyoshi Matsuoka3, Yoon Tae Jeen4, Shu Chen Wei5, Vineet Ahuja6, Minhu Chen7, Pin-Jin Hu8, Akira Andoh9, Hyo Jong Kim10, Suk-Kyun Yang11, Mamoru Watanabe12, Siew Chien Ng13, Toshifumi Hibi14, Ida Normiha Hilmi15, Yasuo Suzuki16, Dong Soo Han17, Wai Keung Leung18, Jose Sollano19, Choon Jin Ooi20, Jiaming Qian21.
Abstract
Inflammatory bowel disease (IBD) has increased in incidence and prevalence in Asian countries since the end of the 20th century. Moreover, differences in the cause, phenotypes, and natural history of IBD between the East and West have been recognized. Therefore, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have established recommendations on medical management of IBD in Asia. Initially, the committee members drafted 40 recommendations, which were then assessed according to Grading of Recommendations Assessment, Development and Evaluation. Eight statements were rejected as this indicated that consensus had not been reached. The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD.Entities:
Keywords: Clostridium difficile; Crohn's disease; biologics; chronic ulcerative colitis; cytomegalovirus; inflammatory bowel disease; intestinal tuberculosis
Year: 2020 PMID: 32672839 DOI: 10.1111/jgh.15185
Source DB: PubMed Journal: J Gastroenterol Hepatol ISSN: 0815-9319 Impact factor: 4.029